Promising
CJC-1295 No DAC (Mod GRF 1-29)
The prediction game
Call it: rising or fading?
Where does CJC-1295 No DAC (Mod GRF 1-29) stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: C (mixed evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 5.8/10
CJC-1295 No DAC sits in caution because it pairs a clean, physiological mechanism with an almost empty human outcomes file and a form that has never been tested in people. If you want a short-acting growth-hormone pulse to stack with ipamorelin, accept that the benefits are unproven, can source verified no-DAC material, and will monitor IGF-1 and glucose, it is a reasonable low-drama experiment. If you expect evidence-backed fat loss or recovery, the data is not there, and the better-supported path is tesamorelin plus ipamorelin, per Falutz 2007. The two biggest real-world frictions are the flushing reaction and unregulated sourcing. ✅ Best for: Experienced users who value a physiological, pulsatile growth-hormone pattern and will run it with ipamorelin. Older adults with lower baseline growth-hormone output, who tend to respond more. People chasing the most consistently reported effect, deeper sleep, who will judge it on their own response over a few weeks. Anyone who can verify they have the no-DAC form by certificate-of-analysis molecular weight and obtain pharmaceutical-grade material. Users who already have training, protein, and sleep dialed in and want a low-suppression add-on. ❌ Avoid if: You have active or hormone-sensitive cancer, since growth-hormone and IGF-1 signaling can promote proliferation. You are pregnant or breastfeeding, with no safety data. You have uncontrolled diabetes or insulin resistance, because growth hormone opposes insulin. You have significant cardiovascular disease, especially if considering the DAC form given its unresolved trial-death history. You compete in tested sport, since growth-hormone-releasing factors are banned at all times under WADA S2. You cannot verify source quality or form, because no-DAC is frequently mislabeled and research-chemical contamination may exceed the intrinsic pharmacological risk.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Promising
- Trend
- Begins with Edition 2
- Momentum
- 0.0%
- BioHarmony Score
- 5.8/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.